Skip to main content

Table 2 Patient comorbidities in the pre-index period

From: Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States

Comorbidities, n (%)

All patients

(N = 172)

Psychiatric disorders

53 (31)

 Depression (including MDD)

32 (19)

 Anxiety disorders (including GAD)

36 (21)

 Depression and anxiety

19 (11)

 Panic disorder

2 (1)

 Bipolar spectrum disorders

8 (5)

Pain

63 (37)

 Fibromyalgia

16 (9)

 Chronic pain

36 (21)

 Back pain

33 (19)

 Neck pain

28 (16)

Sleep disorders

41 (24)

 Insomnia

39 (23)

 Restless leg syndrome

4 (2)

 Sleep apnea

18 (10)

Digestive disorders

28 (16)

 Irritable bowel syndrome

2 (1)

 Constipation

9 (5)

 Ulcer

20 (12)

 Gastroesophageal reflux disease

19 (11)

Respiratory disorders

29 (17)

 Allergies

10 (6)

 Sinusitis

11 (6)

 Bronchitis

2 (1)

 Asthma

17 (10)

Cardiovascular disorders

38 (22)

 Hypertension

28 (16)

 High cholesterol

15 (9)

 Stroke

1 (1)

 Mitral valve prolapse

1 (1)

 Postural orthostatic tachycardia syndrome

2 (1)

Neurologic disorders

8 (5)

 Epilepsy

8 (5)

Autoimmune disorder

2 (1)

 Rheumatoid arthritis

2 (1)

Hormonal disorder

1 (1)

 Polycystic ovarian syndrome

1 (1)

Endocrine disorder

21 (12)

 Diabetes

16 (9)

 Hypothyroidism

7 (4)

Metabolic disorders

18 (10)

 Obesity

18 (10)

  1. MDD major depressive disorder, GAD generalized anxiety disorder